AR064596A1 - Derivados de 4,5-difenilpirrol-2-carboxamida, procedimiento de preparacion, composiciones farmaceuticas y medicamentos que los contienen, y usos en el tratamiento o la prevencion de enfermedades en la que estan implicados los receptores cb1. - Google Patents

Derivados de 4,5-difenilpirrol-2-carboxamida, procedimiento de preparacion, composiciones farmaceuticas y medicamentos que los contienen, y usos en el tratamiento o la prevencion de enfermedades en la que estan implicados los receptores cb1.

Info

Publication number
AR064596A1
AR064596A1 ARP070105123A ARP070105123A AR064596A1 AR 064596 A1 AR064596 A1 AR 064596A1 AR P070105123 A ARP070105123 A AR P070105123A AR P070105123 A ARP070105123 A AR P070105123A AR 064596 A1 AR064596 A1 AR 064596A1
Authority
AR
Argentina
Prior art keywords
group
substituted
unsubstituted
alkyl group
several times
Prior art date
Application number
ARP070105123A
Other languages
English (en)
Inventor
Norberto Judewizc
Christian Congy
Laurent Hortala
Murielle Rinaldi-Carmona
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38521242&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR064596(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of AR064596A1 publication Critical patent/AR064596A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)

Abstract

Un compuesto que corresponde a la formula (1):en la que: A representa un grupo alquileno(C1-C6) no sustituido o sustituido una o varias veces con un grupo alquiloC1-C3);un grupo de formula 2 con m=0, 1 o 2 y p=0 o 1; R1 representa hidrogeno o un alquilo(C1-C4): R2 representa: un grupo alquilo(C3-C10) no sustituido o sustituido con un grupo trifluorometilo: hidroxi o, alcoxi(C1-C4), un átomo de fluor o un grupo CONH2 un radical carbociclico no aromático de C3-C12 no sustituido o sustituido una o varias veces con un grupo alquilo (C1-C4). hidroxilo. ciano alcoxi(C1-C4) o un grupo C0R12 o un átomo de fluor un indanilo:ò un 1,2,3,4 tetrahidronaftalenilo -1 o -2: un radical heterocíclico mono-oxigenado o mono-azufrado de 5 a 7 átomos. no sustituido o sustituido una o varias veces con un grupo alquilo (C1-C4); un radical heterociclico mono-niitrogenaclo. de 5 a 7 átomos, no sustituido o sustituido una o varias veces con un grupo alquilo(C1-C4)_ estando el atomo de nitrogeno sustituido ademas con un grupo alquilo(C1-C4). fenilo, bencilo. alcoxi(C1-C4), carhonilo o alcanoilo(C1-C4). estando los grupos fenilo o bencilo sin sustituir o sustituidos una o varias veces con un átomo de halogeno, un grupo alquilo(C1-C4). trifluorometilo, hidroxilo, o alcoxi(C1 C4); un benzotiofenilo, un indolilo, estando dichos radicales sin sustituir o sustituido una o varias veces con un grupo alquilo(C1-C4); un grupo alquileno(C1-C3) que lleva un radical carbocíclico no aromático de C3-C10 no sustituido o sustituido una o varias veces con un grupo alquilo(C1-C4), hidroxilo, alcoxi(C1-C4). ciano o un grupo COR12: un grupo alquileno(C1-C3) que lleva un radical heterocíclico. heteroaromático o no, mono-oxigenado, mono-azufrado o mono-nitrogenado de 5 a 7 atomos, no sustituido o sustituido una o varias veces con un grupo alquilo(C1-C4): un grupo alquileno(C1-C3) que lleva un radical indolilo o benzotiofenilo, estando dicho radical sin sustituir o sustituido una o varias veces con un grupo alquilo(C1-C4) y estando el alquileno sin sustituir o sustituido con un grupo hidroxilo, metilo o metoxi o con un grupo COR12; un grupo alquileno(C1-C3) que lleva un grupo alquil(C1-C4)tio: un grupo fenilalquileno en el cual el alquileno es de C1-C3, no sustituido o sustituido sobre el alquileno con uno o varios grupos metilo, hidroxilo. hidroximetilo, metoxi. metoximetilo, un grupo COR12 , y no sustituido sobre el fenilo o sustituido sobre el fenilo con uno o varios sustituventes idénticos o diferentes elegidos entre un átomo de halogeno o un grupo alquilo(C1-C4)triflurometilo, alcox j (C1-C4).trifluorometoxiò un grupo bencidrilo o bencidrilmetilo, un grupo NR10R11 o R1y R2 junto con el atomo de nitrogeno al que estan unidos (constituyentes: o bien un grupo morfolinilo, o bien un radical piperazin -1 - ilo o 1,4diazepan- 1 -ilo no sustituido o sustituido con un grupo fenilo, bencilo, benzodioxolilo, benzodioxolilmetilo. tetrahidrofuranilcarhonilo o con un grupo COR12 0 CH2COR12 estando el propio grupo bencilo sin sustituir o sustituido con uno o varios átomos de halogeno o con uno o varios grupos metoxi o metoximetilo: o bien un radical piperidin-1ilo, pirrolidin-1-ilo o azetidin-1-ilo no sustituido o sustituido una o dos veces con un sustituvente elegido cada uno independientemente entre: un átomo de fluor, un grupo alquilo (C1 -C4), hidroxilo, ciano, COR12 NR13R14, NHCOR15. CH2COR12 SO2AIk, o SO2NR13R14: un grupo fenilo, bencilo, piridinilo, estando dichos grupos fenilo, bencilo o piridinilo sin sustituir o sustituidos una o varias veces con un sustituyente elegido cada uno independientemente entre un átomo de halogeno, un grupo metilo, trifluoronietilo, hidroxilo, alcoxi(C1- C4) Y ciano:- y un grupo piperidin-1-ilo, pirrolidin-1-ilo, azetidin-1-ilo. estando dichos grupos piperidin-1-il, pirrolidin -1-ilo o azetidin sin sustituir sustituidos una varias veces con un átomo de fluor, un grupo aquilo C1-4 alcoxi(C1-4) hidroxi. trifluorometilo y OF1 - R3. R4, R5. R5 R6 R7 R8 representan cada uno independientemente uno de otro un átomo de hidrogeno o de halogeno, un grupo CN. S(O)n,AlK, OS(O)nALK un grupo alquilo(C1-C7) no sustituido o sustituido una o varias veces con un sustituyente elegido cada uno independientemente entre un átomo (de fluor, un grupo OALK, S(O)nAI;K, OS(O)nALK y NHSO2AIk. o un grupo alcoxi(C1-6) no sustituido o sustituido con uno o varios sustituyentes elegidos cada uno independientemente entre un átomo de fluor, un grupo OALK. S(O)nALK 1K, S(O)nALK, OSO2AIk; y NHSO2Alk R9 representa un grupo -OH, -CN. -CO2H, NR13R14' -CONR13R14 -NR1COR13, -CONHNH2, -CONHOH. -CONHSO2ÁIk, -S(O)NAIk. -SOCF3.-S02NR13R14, -NR1SO2AIk. -NR1SO2CF3, -NR1SO2N R13R14, o un radical elegido entre:El grupo de formulas (2) R10 representa un átomo de hidrogeno o un grupo metilo: R11 representa un grupo alquilo(C3-C6), fenilo' o cicloalquilo(C3-C10)1 estando dichos grupos fenilo y cicloalquilo sin sustituir o sustituidos con uno o varios sustituyentes elegidos independientemente entre un átomo de halogeno o un grupo alquilo(C1-C4) o trifluorometilo; o R10 y R11 junto con el átomo de nitrogeno al que están unidos constituyen un radical heterocíclico, saturado o insaturado de 4 a 11 átomos, con puente o no que comprende o no un carbono espiránico y que contiene o no segundo heteroátomo elegido entre O o N. estando dicho radical sin sustituir o sustituido una o varias veces con un sustituyente elegido cada uno independientemente entre un grupo hidroxilo. alquilo(C1-4) abcoxi (C1-4)-carhonilo, COR12 Y un grupo fenilo no sustituido o sustituido con uno o varios sustituyentes elegidos cada uno independientemente entre un átomo de halogeno y un grupo alquiloC1-4 R12 representa un grupo alquilo(C1-C4), fenilo, bencilo, alcoxi(C1-4). un trifluorometilo, un grupo NR13R14 R13 y R14 representan cada uno independientemente un átomo de hidrogeno o un grupo alquilo(C1 -C6) opcionalmente sustituido con uno o varios grupos OH.o OALK . o R13 y R14 junto con el átomo de nitrogeno al que están unidos constituyen un radical heterociclico de 4 a 7 miembros que puede llevar un segundo heteroátomo elegido entre un átomo de nitrogeno de oxígeno o de azufre, R15 representa un grupo alquilo(C1-4) o trifluorometilo - n representa 0, 1 o 2; ALK representa un grupo alquilo(C1 -C4) no sustituido o sustituido con uno o varios varios átomos de fluor; Alk representa un grupo alquilo(C1- C4);en el estado de base o de sales de adicion de ácidos. así como en el estado de hidratos o de solvatos.
ARP070105123A 2006-11-20 2007-11-19 Derivados de 4,5-difenilpirrol-2-carboxamida, procedimiento de preparacion, composiciones farmaceuticas y medicamentos que los contienen, y usos en el tratamiento o la prevencion de enfermedades en la que estan implicados los receptores cb1. AR064596A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0610202A FR2908766B1 (fr) 2006-11-20 2006-11-20 Derives de pyrrole,leur preparation et leur utilisation en therapeutique.

Publications (1)

Publication Number Publication Date
AR064596A1 true AR064596A1 (es) 2009-04-15

Family

ID=38521242

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070105123A AR064596A1 (es) 2006-11-20 2007-11-19 Derivados de 4,5-difenilpirrol-2-carboxamida, procedimiento de preparacion, composiciones farmaceuticas y medicamentos que los contienen, y usos en el tratamiento o la prevencion de enfermedades en la que estan implicados los receptores cb1.

Country Status (27)

Country Link
US (1) US8044072B2 (es)
EP (1) EP2094656B1 (es)
JP (1) JP5210320B2 (es)
KR (1) KR20090080992A (es)
CN (1) CN101535250A (es)
AR (1) AR064596A1 (es)
AT (1) ATE520654T1 (es)
AU (1) AU2007330651A1 (es)
BR (1) BRPI0718962A2 (es)
CA (1) CA2669996A1 (es)
CL (1) CL2007003318A1 (es)
CR (1) CR10772A (es)
DO (1) DOP2009000105A (es)
EA (1) EA200970497A1 (es)
EC (1) ECSP099339A (es)
FR (1) FR2908766B1 (es)
IL (1) IL198481A0 (es)
MA (1) MA30996B1 (es)
MX (1) MX2009005366A (es)
NO (1) NO20092066L (es)
PE (1) PE20081495A1 (es)
SV (1) SV2009003265A (es)
TN (1) TN2009000166A1 (es)
TW (1) TW200829565A (es)
UY (1) UY30729A1 (es)
WO (1) WO2008068423A2 (es)
ZA (1) ZA200903865B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2930939B1 (fr) * 2008-05-09 2010-07-30 Sanofi Aventis Derives de pyrrole, leur preparation et leur application en therapeutique
FR2930940B1 (fr) * 2008-05-09 2011-02-11 Sanofi Aventis Derives de pyrrole, leur preparation et leur application en therapeutique
CN102964304B (zh) * 2012-09-28 2015-06-17 苏州大学 含吡唑烷酮结构的手性氨基氰化物的制备方法
RU2711991C1 (ru) * 2016-07-12 2020-01-23 Гуандун Рейновент Биотек Ко., Лтд. Производные пирролидина в качестве агонистов ppar
RU2749056C1 (ru) 2017-12-21 2021-06-03 Гуандун Рэйновент Байотек Ко., Лтд. Аморфное производное пирролидина в качестве агониста ppar и способ его получения
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002319627A1 (en) * 2001-07-20 2003-03-03 Merck And Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
FR2856683A1 (fr) * 2003-06-25 2004-12-31 Sanofi Synthelabo Derives de 4-cyanopyrazole-3-carboxamide, leur preparation et leur application en therapeutique
DK1756066T3 (da) * 2004-05-28 2008-12-15 Solvay Pharm Bv Tetrasubstituerede imidazolderivater som canabinoid-CB1-receptormodulatorer med höj CB1/CB2-receptorundertypeselektivitet
FR2874012B1 (fr) * 2004-08-09 2008-08-22 Sanofi Synthelabo Derives de pyrrole, leur preparation et leur utlisation en therapeutique
FR2881744B1 (fr) * 2005-02-09 2007-04-27 Sanofi Aventis Sa Derives de n-[(4,5-diphenyl-2-thienyl)methyl]amine, leur preparation et leur application en therapeutique
JP2008530179A (ja) * 2005-02-16 2008-08-07 ソルベイ・フアーマシユーチカルズ・ベー・ブイ カンナビノイドｃｂ２受容体モジュレーターとしての１ｈ−イミダゾール誘導体

Also Published As

Publication number Publication date
JP5210320B2 (ja) 2013-06-12
WO2008068423A3 (fr) 2008-07-31
TW200829565A (en) 2008-07-16
JP2010510198A (ja) 2010-04-02
EP2094656B1 (fr) 2011-08-17
US20090281116A1 (en) 2009-11-12
PE20081495A1 (es) 2008-12-31
CN101535250A (zh) 2009-09-16
EA200970497A1 (ru) 2009-10-30
FR2908766A1 (fr) 2008-05-23
CR10772A (es) 2009-07-23
WO2008068423A2 (fr) 2008-06-12
ZA200903865B (en) 2010-08-25
TN2009000166A1 (fr) 2010-10-18
ECSP099339A (es) 2009-06-30
DOP2009000105A (es) 2009-05-31
EP2094656A2 (fr) 2009-09-02
CA2669996A1 (fr) 2008-06-12
AU2007330651A1 (en) 2008-06-12
BRPI0718962A2 (pt) 2013-12-17
MA30996B1 (fr) 2009-12-01
FR2908766B1 (fr) 2009-01-09
CL2007003318A1 (es) 2008-07-04
UY30729A1 (es) 2008-07-03
NO20092066L (no) 2009-08-11
US8044072B2 (en) 2011-10-25
ATE520654T1 (de) 2011-09-15
MX2009005366A (es) 2009-06-08
KR20090080992A (ko) 2009-07-27
SV2009003265A (es) 2010-02-05
IL198481A0 (en) 2010-02-17

Similar Documents

Publication Publication Date Title
AR064596A1 (es) Derivados de 4,5-difenilpirrol-2-carboxamida, procedimiento de preparacion, composiciones farmaceuticas y medicamentos que los contienen, y usos en el tratamiento o la prevencion de enfermedades en la que estan implicados los receptores cb1.
AR069796A1 (es) Derivados de bencimidazol, sustituido por carboxilo o por hidroxilo, proceso para prepararlos y composiciones farmaceuticas que los contienen
CR8468A (es) Derivado de n-(1,5-difenil-1h-pirazol-3-il)metil)sulfonamida con afinidad por los receptores cb1
AR040498A1 (es) Indoles sustituidos utiles para el tratamiento de enfermedades respiratorias
AR066669A1 (es) Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas.
PE20080830A1 (es) Compuestos derivados de sulfonilo que modulan el receptor cb2
AR078163A1 (es) Utilizacion de aminodihidrotiazinas para el tratamiento o prevencion de la diabetes
AR061651A1 (es) Analogos de piridina ii
AR058010A1 (es) Derivados biciclicos como inhibidores de p38 y composicion farmaceutica en base al compuesto
AR053186A1 (es) Derivados del 1- bencil indol carboxamida
AR037907A1 (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
AR044614A1 (es) Composiciones de sulfonamida que modulan la actividad del receptor de quinioquinas (ccr4)
CU20110169A7 (es) Nuevos derivados de benzotiadiazepinas, su procedimiento de preparación y composiciones farmacéuticas que los contienen
AR045155A1 (es) Derivados de 6-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos
AR050341A1 (es) Compuestos derivados de piperidina, composicion farmaceutica en base al compuesto y su uso para preparar medicamentos
PE20050416A1 (es) Compuestos de 4-fenil piperidina y sus usos como modulador de receptores opioides
CO6270319A2 (es) Benzotiazoles como moduladores del receptor de ghrelina
AR042362A1 (es) Derivados de 3h-quinazolin-4-ona, proceso de obtencion y composiciones farmaceuticas que los contienen
CO5660263A2 (es) Derivados de imidazol heteroaril sustituidos como antagonistas del receptor de glutamato
AR065180A1 (es) Derivados de indol - 2 - il - piperazin - 1 - il - metanona y composicion farmaceutica
AR056874A1 (es) Derivados de 6- heteroarilpiridoindolona, su preparacion y su aplicacion en terapeutica
DOP2006000133A (es) Derivados de 4,5 diarilpiroxol, su preparación y su aplicación en terapeútica
AR052332A1 (es) Derivados de benzdioxanpiperazina con una afinidad combinada para receptores de dopamina-d2 y sitios de reabsorcion de serotonina, composiciones farmaceuticas que los contienen y su empleo como medicamentos para el tratamiento de enfermedades del snc
AR050447A1 (es) Derivados de pirrol, su preparacion y su aplicacion en terapeutica.
BR112013007145A2 (pt) composto ou sal farmacologicamente aceitável, medicamento, e, uso do composto ou sal farmacologicamente aceitável

Legal Events

Date Code Title Description
FB Suspension of granting procedure